CJC-1295 (Modified GRF 1-29)

Growth Hormone / IGF-1 Axis
Discontinued
Investigational

CJC-1295 without DAC (also called Modified GRF 1-29) is a synthetic growth hormone-releasing compound with a short active window of about 30 minutes. It is being studied for its effects on growth hormone release and body composition.

Last updated March 6, 2026
28 PubMed-Verified Studies
Very Popular
Research-Driven Dosage Reports
RouteSubcutaneous (SC)
Dose100–300 mcg (no DAC)
Frequency1–3× daily
Duration8–12 weeks

Based on published research literature.

Verified sources for CJC-1295 (Modified GRF 1-29)

These vendors are vetted by PeptideWiki for purity testing and COA transparency.

SwissChems10% off
View all vendor deals·Affiliate links. Commission at no extra cost.

Overview of CJC-1295 (Modified GRF 1-29)

Stimulates growth hormone release by activating GHRH receptors on pituitary cells, leading to elevated IGF-1 and anabolic effects.

Growth hormone axis

Binds to GHRH receptors on pituitary somatotroph cells, triggering signaling cascades that promote GH synthesis and release.

Stimulates pulsatile GH secretion, leading to 2-10x elevation in circulating growth hormone levels.

Increases hepatic IGF-1 production, mediating anabolic effects on muscle, bone, and connective tissue.

Formulation differences

With DAC (Drug Affinity Complex): Contains lysine linker binding albumin, extending half-life to several days for sustained GH elevation.

Without DAC (Mod GRF 1-29): Shorter half-life (~30 minutes), which may better preserve natural pulsatile GH release patterns.

Synergy / stacking

Often combined with ghrelin mimetics like Ipamorelin (proposed), amplifying GH release through complementary receptor pathways

Read Full CJC-1295 (Modified GRF 1-29) Dosage Guide

Research-backed dosing protocols, timing, and administration details

Browse more in this category

Growth Hormone / IGF-1 Axis